In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From CardioLogical Solutions

Lilly Inks Follow-Up Radiopharmaceuticals Deal With Aktis

The big pharma will pay $60m upfront and make an equity investment in the Boston-based startup.

Deals Cancer

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Market Intelligence Commercial

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.

M & A Business Strategies

Big Pharma Oncology Strategies Aim To Treat Cancer Earlier

ADCs, radiopharmaceuticals, precision medicines and T-cell engagers dominated R&D pipelines reviewed by 12 big pharmas at the first annual AACR Oncology Industry Partnering Event.

Cancer Strategy
See All

Company Information

  • Other Names / Subsidiaries
    • Emboline, VasoStitch
UsernamePublicRestriction

Register